146 related articles for article (PubMed ID: 19061286)
1. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
[TBL] [Abstract][Full Text] [Related]
2. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
Zendehrokh N; Dejmek A
Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
[TBL] [Abstract][Full Text] [Related]
3. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
[TBL] [Abstract][Full Text] [Related]
4. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
Adell E; Dejmek A
Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
[TBL] [Abstract][Full Text] [Related]
5. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
[TBL] [Abstract][Full Text] [Related]
6. Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions.
Zendehrokh N; Rehnberg J; Dejmek A
Acta Cytol; 2007; 51(6):886-92. PubMed ID: 18077981
[TBL] [Abstract][Full Text] [Related]
7. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
[TBL] [Abstract][Full Text] [Related]
8. In situ telomerase activity in pleural effusions: a promising marker for malignancy.
Dejmek A; Yahata N; Ohyashiki K; Ebihara Y; Kakihana M; Hirano T; Kawate N; Kato H
Diagn Cytopathol; 2001 Jan; 24(1):11-5. PubMed ID: 11135462
[TBL] [Abstract][Full Text] [Related]
9. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
10. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
Davidson B; Stavnes HT; Hellesylt E; Hager T; Zeppa P; Pinamonti M; Wohlschlaeger J
Hum Pathol; 2016 Jan; 47(1):104-8. PubMed ID: 26520416
[TBL] [Abstract][Full Text] [Related]
11. Detection of telomerase status by semiquantitative and in situ assays, and by real-time reverse transcription-polymerase chain reaction (telomerase reverse transcriptase) assay in bladder carcinomas.
Longchampt E; Lebret T; Molinie V; Bieche I; Botto H; Lidereau R
BJU Int; 2003 Apr; 91(6):567-72. PubMed ID: 12656916
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity in pleural malignant mesotheliomas.
Au AY; Hackl T; Yeager TR; Cohen SB; Pass HI; Harris CC; Reddel RR
Lung Cancer; 2011 Sep; 73(3):283-8. PubMed ID: 21277646
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activity in human pleural mesothelioma.
Dhaene K; Hübner R; Kumar-Singh S; Weyn B; Van Marck E
Thorax; 1998 Nov; 53(11):915-8. PubMed ID: 10193387
[TBL] [Abstract][Full Text] [Related]
14. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
15. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
Nagel H; Schlott T; Schulz GM; Droese M
Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
[TBL] [Abstract][Full Text] [Related]
16. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
Nieh S; Chen SF; Fu E; Jan CI; Lee WH
Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
[TBL] [Abstract][Full Text] [Related]
17. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic implications of telomerase activity in pleural effusions.
Dikmen G; Dikmen E; Kara M; Sahin E; Doğan P; Ozdemir N
Eur Respir J; 2003 Sep; 22(3):422-6. PubMed ID: 14516130
[TBL] [Abstract][Full Text] [Related]
19. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity.
Hou M; Xu D; Björkholm M; Gruber A
Clin Chem; 2001 Mar; 47(3):519-24. PubMed ID: 11238306
[TBL] [Abstract][Full Text] [Related]
20. TRAP-LIG, a modified telomere repeat amplification protocol assay to quantitate telomerase inhibition by small molecules.
Reed J; Gunaratnam M; Beltran M; Reszka AP; Vilar R; Neidle S
Anal Biochem; 2008 Sep; 380(1):99-105. PubMed ID: 18534183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
